12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Next-generation Epi proColon: Feasibility study data

Epigenomics reported data from a feasibility study evaluating blood samples from 97 colorectal cancer patients and 159 colonoscopy-confirmed healthy controls showing that its next-generation Epi proColon test had 91% sensitivity and 87% specificity for detecting colorectal cancer. Additionally, the assay was able to identify 78% of stage I cancer cases...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >